Tag: ppms treatment market share

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

#Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Expansion Outlook: What Revenue Opportunities Are Ahead?#_x000D_

The primary progressive multiple sclerosis (ppms) treatment market size has experienced swift growth in recent years. It is projected to increase from $1.16 billion in 2025 to $1.31 billion in 2026, at a compound annual growth rate (CAGR) of 13.7%. The historical growth in this market can be attributed to factors such as limited treatment options for ppms, a reliance on corticosteroids for symptom management, low awareness of ppms among patients, underdeveloped hospital pharmacy infrastructure, and the slow adoption of immunosuppressants._x000D_

_x000D_

The primary progressive multiple sclerosis (ppms) treatment market is projected for substantial expansion in the upcoming years, with its valuation expected to reach $2.18 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.5%. This anticipated growth during the forecast period is attributed to factors such as the introduction of targeted monoclonal antibodies, a surge in research and development activities for neurodegenerative disorders, the expansion of hospital and online pharmacy networks, an increase in regulatory approvals for novel therapeutics, and enhanced patient awareness and early diagnosis programs. Key trends anticipated in the same period include the rising adoption of monoclonal antibodies for ppms, an increased focus on symptom management and quality of life, a growing preference for intravenous drug administration, the expansion of hospital and specialty pharmacy channels, and the development of novel therapeutics and combination therapies._x000D_

_x000D_

#Get A Free Sample Report With In-Depth Market Insights:#_x000D_

https://thebusinessresearchcompany.com/sample_request?id=90215028&type=smp&name=Primary%20Progressive%20Multiple%20Sclerosis%20%28PPMS%29%20Treatment%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Growth Catalysts And Demand Drivers#_x000D_

The increasing need for effective treatments is projected to fuel the expansion of the primary progressive multiple sclerosis (PPMS) treatment market in the future. Effective treatments are medical interventions aimed at alleviating symptoms, improving patient results, or curing a disease or condition. This rising demand for successful therapies is predominantly driven by the growing prevalence of chronic and complex health conditions, which necessitate long-term management and advanced therapeutic solutions to enhance patient outcomes and quality of life. Effective treatments contribute to slowing the progression of primary progressive multiple sclerosis (PPMS) by targeting inflammation and preserving neurological function, thereby enhancing long-term quality of life, reducing disability accumulation, and improving patients’ ability to manage daily activities with greater independence and stability. For instance, in January 2024, the American Society of Gene & Cell Therapy, a US-based organization focused on gene and cell therapy, reported that the number of gene therapies in Phase III clinical trials reached 33 Phase III gene therapy trials in 2023, representing a 10% increase compared to 2022, and marked the first quarterly increase since Q3 2022. Therefore, the growing demand for effective treatments is a key driver for the primary progressive multiple sclerosis (PPMS) treatment market’s growth._x000D_

_x000D_

#Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Breakdown By Product Type And Application#_x000D_

The primary progressive multiple sclerosis (ppms) treatment market covered in this report is segmented – _x000D_

_x000D_

1) By Drug Type: Monoclonal Antibodies, Immunosuppressants, Corticosteroids, Other Drug Types_x000D_

2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations_x000D_

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels_x000D_

_x000D_

Subsegments:_x000D_

1) By Monoclonal Antibodies: Ocrelizumab, Rituximab, Ofatumumab, Ublituximab_x000D_

2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide_x000D_

3) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone, Hydrocortisone_x000D_

4) By Other Drug Types: Biotin, Ibudilast, Laquinimod, Idebenone_x000D_

_x000D_

#Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Trends Shaping Long-Term Demand#_x000D_

Major companies in the primary progressive multiple sclerosis (PPMS) treatment market are prioritizing the development of innovative formulations, such as monoclonal antibody drugs, to enhance multiple sclerosis treatment. A monoclonal antibody drug aids in multiple sclerosis by precisely targeting particular immune cells or proteins that induce inflammation and harm to the nervous system, thus diminishing disease activity and decelerating symptom progression. For example, in February 2024, Roche Pharma India, an India-based pharmaceutical firm, introduced Ocrevus (ocrelizumab), a monoclonal antibody drug, for multiple sclerosis (MS) treatment in India. Ocrevus is significant as the first and only approved disease-modifying therapy (DMT) for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in the nation. The medication functions by targeting CD20-positive B cells, an immune cell type implicated in the abnormal immune response characteristic of MS. It is administered via a twice-yearly intravenous infusion lasting only two hours, presenting patients with a more convenient and effective treatment choice._x000D_

_x000D_

#Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Company Landscape And Competitive Strategy#_x000D_

Major companies operating in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Biogen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, BrainStorm Cell Therapeutics Inc., TG Therapeutics Inc., EMD Serono Inc. (Merck KGaA), Mitsubishi Tanabe Pharma Corporation, Sanofi Genzyme, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Viela Bio (Horizon Therapeutics), Receptos (Celgene/Bristol-Myers Squibb), Forward Pharma A/S, InnoCare Pharma, NervGen Pharma Corp., Priovant Therapeutics, Tiziana Life Sciences, Reata Pharmaceuticals, Biohaven Pharmaceutical Holding Company, Anokion SA _x000D_

_x000D_

#View The Full Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Report:#_x000D_

https://thebusinessresearchcompany.com/report/primary-progressive-multiple-sclerosis-ppms-treatment-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Regional Analysis And Leading Geography#_x000D_

North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (ppms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Reach Out To Our Team:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas: +1 310-496-7795_x000D_

Asia: +44 7882 955267 & +91 8897263534_x000D_

Europe: +44 7882 955267_x000D_

Email us at: marketing@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Primary Progressive Multiple Sclerosis (PPMS) Treatment Market CAGR Analysis And Future Market Development

The market for primary progressive multiple sclerosis (PPMS) therapies has expanded quickly in recent years. It is projected to increase from $1.16 billion in 2025 to $1.31 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.7%. Historical expansion has been driven by factors such as the scarcity of treatment alternatives for PPMS, the dependence on corticosteroids to manage symptoms, limited patient awareness of the condition, underdeveloped hospital pharmacy systems, and the gradual uptake of immunosuppressants.

The primary progressive multiple sclerosis (PPMS) treatment market is poised for substantial expansion in the coming years. By 2030, its value is projected to reach $2.18 billion, reflecting a compound annual growth rate (CAGR) of 13.5%. This anticipated growth during the forecast period is driven by factors such as the launch of targeted monoclonal antibodies, heightened research and development efforts in neurodegenerative conditions, the broadening of hospital and online pharmacy networks, an increase in regulatory approvals for innovative treatments, and enhanced patient awareness coupled with early diagnosis initiatives. Key trends shaping this period include a growing preference for monoclonal antibodies in PPMS management, a stronger emphasis on alleviating symptoms and improving quality of life, a shift toward intravenous drug administration, the expansion of hospital and specialty pharmacy channels, and the continuous development of novel therapeutics and combination approaches.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24670&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Growth Drivers: What Factors Are Accelerating Expansion?

The rising necessity for impactful therapies is anticipated to fuel expansion in the primary progressive multiple sclerosis (PPMS) treatment market moving ahead. Impactful therapies refer to medical approaches that alleviate symptoms, enhance patient outcomes, or eliminate a disease or condition. This growing necessity is largely propelled by the increasing occurrence of chronic and intricate health issues that call for sustained management and advanced medical solutions to boost patient results and life quality. By addressing inflammation and safeguarding neurological function, such therapies decelerate PPMS progression, thus elevating long-term life quality, curbing disability accumulation, and empowering individuals to handle daily tasks with greater autonomy and steadiness. For example, data from January 2024 released by the American Society of Gene & Cell Therapy—a US-focused organization dedicated to gene and cell therapy—showed that the number of gene therapies in Phase III clinical trials hit 33 in 2023, marking a 10% rise from 2022 and the first quarterly uptick since Q3 2022. Consequently, the escalating demand for impactful therapies is steering the growth of the primary progressive multiple sclerosis (PPMS) treatment market.

Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Segment Landscape And Growth Potential

The primary progressive multiple sclerosis (ppms) treatment market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Immunosuppressants, Corticosteroids, Other Drug Types

2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Ocrelizumab, Rituximab, Ofatumumab, Ublituximab

2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide

3) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone, Hydrocortisone

4) By Other Drug Types: Biotin, Ibudilast, Laquinimod, Idebenone

Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Trends: What Is Shaping Future Industry Growth?

Within the primary progressive multiple sclerosis (PPMS) treatment market, key players are placing significant emphasis on creating novel formulations, particularly monoclonal antibody drugs, aimed at improving multiple sclerosis care. These monoclonal antibody therapies function by specifically binding to immune cells or proteins responsible for triggering inflammation and neural damage, thereby minimizing disease activity and decelerating symptom progression. A concrete example is provided by Roche Pharma India, headquartered in India, which introduced Ocrevus (ocrelizumab) in February 2024 for treating multiple sclerosis (MS) within the country. Ocrevus distinguishes itself as the first and only approved disease-modifying therapy (DMT) that addresses both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in the Indian market. Its mechanism of action involves targeting CD20-positive B cells—immune cells implicated in the aberrant immune responses characteristic of MS. Administration occurs through a twice-yearly intravenous infusion lasting just two hours, delivering a more convenient yet highly effective treatment alternative for patients.

Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Biogen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, BrainStorm Cell Therapeutics Inc., TG Therapeutics Inc., EMD Serono Inc. (Merck KGaA), Mitsubishi Tanabe Pharma Corporation, Sanofi Genzyme, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Viela Bio (Horizon Therapeutics), Receptos (Celgene/Bristol-Myers Squibb), Forward Pharma A/S, InnoCare Pharma, NervGen Pharma Corp., Priovant Therapeutics, Tiziana Life Sciences, Reata Pharmaceuticals, Biohaven Pharmaceutical Holding Company, Anokion SA

Access The Complete Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/primary-progressive-multiple-sclerosis-ppms-treatment-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (ppms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Estimated Growth In Market Size Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market During 2026–2030?

The primary progressive multiple sclerosis (ppms) treatment market has experienced rapid expansion in recent years. It is projected to grow from $1.16 billion in 2025 to $1.31 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.7%. Historically, this growth was influenced by factors such as the restricted availability of treatment options for ppms, the dependence on corticosteroids for managing symptoms, insufficient patient awareness of ppms, an underdeveloped hospital pharmacy infrastructure, and the slow integration of immunosuppressants.

The primary progressive multiple sclerosis (ppms) treatment market is projected to experience substantial expansion over the coming years. It is forecast to reach $2.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.5%. This anticipated growth during the forecast period is largely due to factors such as the introduction of targeted monoclonal antibodies, intensified research and development efforts in neurodegenerative disorders, the broadening reach of hospital and online pharmacy networks, an increase in regulatory approvals for new therapeutic options, and enhanced patient awareness and early diagnosis initiatives. Key trends expected during this period involve the increasing uptake of monoclonal antibodies for ppms, a heightened emphasis on symptom management and improving quality of life, a growing preference for intravenous drug administration, the expansion of hospital and specialty pharmacy channels, and the ongoing development of innovative therapeutics and combination treatments.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24670&type=smp

What Major Growth Factors Are Impacting The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

The increasing need for successful therapies is projected to boost the primary progressive multiple sclerosis (PPMS) treatment market going forward. Effective treatments are medical interventions that lessen symptoms, improve patient results, or cure a disease or condition. This rising demand is primarily fueled by the growing occurrence of chronic and complex health conditions, which require sustained management and advanced therapeutic interventions to enhance patient outcomes and quality of life. Such treatments are vital for slowing the progression of primary progressive multiple sclerosis (PPMS) by targeting inflammation and preserving neurological function, thus improving long-term quality of life, reducing disability accumulation, and empowering patients to manage daily activities with greater independence and stability. For example, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization focused on gene and cell therapy, the number of gene therapies in Phase III clinical trials reached 33 trials in 2023, representing a 10% increase compared to 2022 and the first quarterly rise since Q3 2022. Consequently, the growing demand for effective treatments is a key driver for the primary progressive multiple sclerosis (PPMS) treatment market.

What Key Segment Areas Are Included In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Assessment?

The primary progressive multiple sclerosis (ppms) treatment market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Immunosuppressants, Corticosteroids, Other Drug Types

2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Ocrelizumab, Rituximab, Ofatumumab, Ublituximab

2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide

3) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone, Hydrocortisone

4) By Other Drug Types: Biotin, Ibudilast, Laquinimod, Idebenone

Which Trends Are Supporting The Evolution Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

Leading companies in the primary progressive multiple sclerosis (PPMS) treatment market are concentrating on creating advanced formulations, including monoclonal antibody drugs, to improve therapy for multiple sclerosis. A monoclonal antibody drug supports multiple sclerosis patients by targeting specific immune cells or proteins that trigger inflammation and harm the nervous system, thereby lessening disease activity and slowing the progression of symptoms. As an illustration, in February 2024, Roche Pharma India, a pharmaceutical company based in India, launched Ocrevus (ocrelizumab), a monoclonal antibody drug, for treating multiple sclerosis (MS) within India. Ocrevus stands out as the first and only approved disease-modifying therapy (DMT) in the country for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). This medication operates by targeting CD20-positive B cells, a type of immune cell involved in the abnormal immune response observed in MS. It is delivered as a twice-yearly intravenous infusion over only two hours, presenting patients with a more convenient and effective treatment choice.

Who Are The Prominent Players Across The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

Major companies operating in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Biogen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, BrainStorm Cell Therapeutics Inc., TG Therapeutics Inc., EMD Serono Inc. (Merck KGaA), Mitsubishi Tanabe Pharma Corporation, Sanofi Genzyme, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Viela Bio (Horizon Therapeutics), Receptos (Celgene/Bristol-Myers Squibb), Forward Pharma A/S, InnoCare Pharma, NervGen Pharma Corp., Priovant Therapeutics, Tiziana Life Sciences, Reata Pharmaceuticals, Biohaven Pharmaceutical Holding Company, Anokion SA

Access The Complete Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/primary-progressive-multiple-sclerosis-ppms-treatment-global-market-report

Which Region Leads The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market By Size?

North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (ppms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24670&type=smp

Browse Through More Reports Similar to the Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market 2026, By The Business Research Company

Multiple Sclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report

Atherosclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

Focal Segmental Glomerulosclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/focal-segmental-glomerulosclerosis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market From 2026 To 2030?

The primary progressive multiple sclerosis (ppms) treatment market size has seen swift expansion in recent years. It is anticipated to increase from $1.16 billion in 2025 to $1.31 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.7%. This historical growth can be linked to factors including restricted treatment options for ppms, a reliance on corticosteroids for managing symptoms, limited patient awareness of ppms, an underdeveloped hospital pharmacy infrastructure, and the slow integration of immunosuppressants.

The primary progressive multiple sclerosis (ppms) treatment market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $2.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.5%. Factors contributing to this projected growth include the introduction of targeted monoclonal antibodies, a rise in research and development efforts for neurodegenerative disorders, the expansion of hospital and online pharmacy channels, an increase in regulatory approvals for new treatments, and enhanced patient awareness along with early diagnosis initiatives. Key trends anticipated during this period encompass the growing acceptance of monoclonal antibodies for PPMS, a heightened emphasis on symptom control and improving patients’ quality of life, a rising preference for intravenous drug delivery, the enlargement of hospital and specialty pharmacy avenues, and the innovation of new therapeutics and combined treatment approaches.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24670&type=smp

What Factors Are Contributing To The Growth Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

The future expansion of the primary progressive multiple sclerosis (PPMS) treatment market is anticipated to be fueled by the increasing need for efficacious therapies. Such therapies represent medical interventions designed to alleviate symptoms, enhance patient results, or eradicate a disease or ailment. This escalating requirement for effective treatments primarily stems from the growing incidence of chronic and intricate health issues, which necessitate ongoing management and sophisticated therapeutic approaches to elevate patient outcomes and living standards. For primary progressive multiple sclerosis (PPMS), effective treatments are instrumental in decelerating disease progression by addressing inflammation and safeguarding neurological function. This, in turn, leads to an improved long-term quality of life, diminished disability progression, and a greater capacity for patients to independently and stably conduct daily activities. As an illustration, in January 2024, the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, reported that gene therapies in Phase III clinical trials totaled 33 Phase III gene therapy trials in 2023, reflecting a 10% rise from 2022 and marking the initial quarterly increase since Q3 2022. Consequently, the rising demand for effective treatments is a key driver for the growth of the primary progressive multiple sclerosis (PPMS) treatment market.

How Are Segments Identified Within The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Segment Framework?

The primary progressive multiple sclerosis (ppms) treatment market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Immunosuppressants, Corticosteroids, Other Drug Types

2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Ocrelizumab, Rituximab, Ofatumumab, Ublituximab

2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide

3) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone, Hydrocortisone

4) By Other Drug Types: Biotin, Ibudilast, Laquinimod, Idebenone

What Emerging Trends Are Seen In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

Leading companies within the primary progressive multiple sclerosis (PPMS) treatment market are intensifying their efforts to develop cutting-edge formulations, such as monoclonal antibody drugs, to improve multiple sclerosis therapy. A monoclonal antibody drug works in multiple sclerosis by targeting specific immune cells or proteins that contribute to inflammation and nerve damage, thereby decreasing disease activity and slowing symptom progression. For instance, in February 2024, Roche Pharma India, an India-based pharmaceutical company, launched Ocrevus (ocrelizumab), a monoclonal antibody drug, for the treatment of multiple sclerosis (MS) in India. Ocrevus is significant as the first and only approved disease-modifying therapy (DMT) available in the country for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). The medication operates by targeting CD20-positive B cells, an immune cell type involved in the aberrant immune response observed in MS. It is administered via a twice-yearly intravenous infusion lasting only two hours, offering patients a more convenient and effective treatment choice.

Who Are The Companies Competing Within The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

Major companies operating in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Biogen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, BrainStorm Cell Therapeutics Inc., TG Therapeutics Inc., EMD Serono Inc. (Merck KGaA), Mitsubishi Tanabe Pharma Corporation, Sanofi Genzyme, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Viela Bio (Horizon Therapeutics), Receptos (Celgene/Bristol-Myers Squibb), Forward Pharma A/S, InnoCare Pharma, NervGen Pharma Corp., Priovant Therapeutics, Tiziana Life Sciences, Reata Pharmaceuticals, Biohaven Pharmaceutical Holding Company, Anokion SA

Get The Full Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/primary-progressive-multiple-sclerosis-ppms-treatment-global-market-report

Which Geographic Region Dominates The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (ppms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/primary-progressive-multiple-sclerosis-ppms-treatment-global-market-report

Browse Through More Reports Similar to the Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market 2026, By The Business Research Company

Multiple Sclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report

Atherosclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

Focal Segmental Glomerulosclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/focal-segmental-glomerulosclerosis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The market for primary progressive multiple sclerosis (ppms) treatments has experienced swift expansion recently. This market is projected to expand from $1.16 billion in 2025 to $1.31 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.7%. Historically, this growth can be ascribed to factors such as restricted treatment options for ppms, the dependence on corticosteroids for managing symptoms, inadequate patient awareness of ppms, an underdeveloped hospital pharmacy infrastructure, and the gradual uptake of immunosuppressants.

The primary progressive multiple sclerosis (ppms) treatment market is projected to expand significantly in the coming years, reaching $2.18 billion by 2030, driven by a compound annual growth rate (CAGR) of 13.5%. This anticipated expansion throughout the forecast period can be ascribed to several factors, including the emergence of targeted monoclonal antibodies, heightened research and development efforts in neurodegenerative conditions, the broadening of hospital and online pharmacy infrastructures, a surge in regulatory approvals for new treatments, and enhanced patient awareness and early detection initiatives. Key trends expected during this period involve an increasing uptake of monoclonal antibodies for ppms, a greater emphasis on managing symptoms and improving quality of life, a growing preference for intravenous drug delivery, the expansion of hospital and specialty pharmacy networks, and the creation of innovative therapeutics and combination treatments.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24670&type=smp

What Key Drivers Are Influencing The Growth Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

The primary progressive multiple sclerosis (PPMS) treatment market is projected to grow in the future due to the increasing need for effective treatments. These treatments are medical interventions that lessen symptoms, improve patient results, or cure a disease or condition. The rising demand for effective treatments is primarily fueled by the increasing occurrence of chronic and complex health conditions, which necessitate sustained management and advanced therapeutic interventions to enhance patient outcomes and quality of life. Specifically for primary progressive multiple sclerosis (PPMS), effective treatments aid in slowing its advancement by targeting inflammation and maintaining neurological function, thereby enhancing long-term quality of life, minimizing disability buildup, and boosting patients’ capacity to manage daily activities with greater independence and stability. As an example, in January 2024, as reported by the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, the count of gene therapies in Phase III clinical trials reached 33 Phase III gene therapy trials in 2023, which was an increase of 10% compared to 2022, marking the first quarterly increase since Q3 2022. Consequently, the escalating demand for effective treatments propels the expansion of the primary progressive multiple sclerosis (PPMS) treatment market.

What Major Segment Divisions Exist Within The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

The primary progressive multiple sclerosis (ppms) treatment market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Immunosuppressants, Corticosteroids, Other Drug Types

2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Ocrelizumab, Rituximab, Ofatumumab, Ublituximab

2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide

3) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone, Hydrocortisone

4) By Other Drug Types: Biotin, Ibudilast, Laquinimod, Idebenone

How Are Trends Shaping The Direction Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

Leading companies in the primary progressive multiple sclerosis (PPMS) treatment market are focusing on creating advanced formulations, such as monoclonal antibody drugs, to improve multiple sclerosis therapy. A monoclonal antibody drug aids in multiple sclerosis by specifically targeting immune cells or proteins that initiate inflammation and harm the nervous system, thereby reducing disease activity and slowing the advancement of symptoms. For instance, in February 2024, Roche Pharma India, an India-based pharmaceutical company, introduced Ocrevus (ocrelizumab), a monoclonal antibody drug, for treating multiple sclerosis (MS) in India. Ocrevus is significant as the first and only approved disease-modifying therapy (DMT) for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in the country. The drug operates by targeting CD20-positive B cells, a type of immune cell involved in the abnormal immune response observed in MS. It is administered as a twice-yearly intravenous infusion for only two hours, providing patients with a more convenient and effective treatment alternative.

Which Companies Are Leading Innovation In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

Major companies operating in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Biogen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, BrainStorm Cell Therapeutics Inc., TG Therapeutics Inc., EMD Serono Inc. (Merck KGaA), Mitsubishi Tanabe Pharma Corporation, Sanofi Genzyme, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Viela Bio (Horizon Therapeutics), Receptos (Celgene/Bristol-Myers Squibb), Forward Pharma A/S, InnoCare Pharma, NervGen Pharma Corp., Priovant Therapeutics, Tiziana Life Sciences, Reata Pharmaceuticals, Biohaven Pharmaceutical Holding Company, Anokion SA

Read the full primary progressive multiple sclerosis (ppms) treatment market report here:

https://www.thebusinessresearchcompany.com/report/primary-progressive-multiple-sclerosis-ppms-treatment-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (ppms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24670&type=smp

Browse Through More Reports Similar to the Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market 2026, By The Business Research Company

Multiple Sclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report

Atherosclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

Focal Segmental Glomerulosclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/focal-segmental-glomerulosclerosis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The market for primary progressive multiple sclerosis (ppms) treatments has experienced swift expansion recently. This market is projected to expand from $1.16 billion in 2025 to $1.31 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.7%. Historically, this growth can be ascribed to factors such as restricted treatment options for ppms, the dependence on corticosteroids for managing symptoms, inadequate patient awareness of ppms, an underdeveloped hospital pharmacy infrastructure, and the gradual uptake of immunosuppressants.

The primary progressive multiple sclerosis (ppms) treatment market is projected to expand significantly in the coming years, reaching $2.18 billion by 2030, driven by a compound annual growth rate (CAGR) of 13.5%. This anticipated expansion throughout the forecast period can be ascribed to several factors, including the emergence of targeted monoclonal antibodies, heightened research and development efforts in neurodegenerative conditions, the broadening of hospital and online pharmacy infrastructures, a surge in regulatory approvals for new treatments, and enhanced patient awareness and early detection initiatives. Key trends expected during this period involve an increasing uptake of monoclonal antibodies for ppms, a greater emphasis on managing symptoms and improving quality of life, a growing preference for intravenous drug delivery, the expansion of hospital and specialty pharmacy networks, and the creation of innovative therapeutics and combination treatments.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24670&type=smp

What Key Drivers Are Influencing The Growth Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

The primary progressive multiple sclerosis (PPMS) treatment market is projected to grow in the future due to the increasing need for effective treatments. These treatments are medical interventions that lessen symptoms, improve patient results, or cure a disease or condition. The rising demand for effective treatments is primarily fueled by the increasing occurrence of chronic and complex health conditions, which necessitate sustained management and advanced therapeutic interventions to enhance patient outcomes and quality of life. Specifically for primary progressive multiple sclerosis (PPMS), effective treatments aid in slowing its advancement by targeting inflammation and maintaining neurological function, thereby enhancing long-term quality of life, minimizing disability buildup, and boosting patients’ capacity to manage daily activities with greater independence and stability. As an example, in January 2024, as reported by the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, the count of gene therapies in Phase III clinical trials reached 33 Phase III gene therapy trials in 2023, which was an increase of 10% compared to 2022, marking the first quarterly increase since Q3 2022. Consequently, the escalating demand for effective treatments propels the expansion of the primary progressive multiple sclerosis (PPMS) treatment market.

What Major Segment Divisions Exist Within The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

The primary progressive multiple sclerosis (ppms) treatment market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Immunosuppressants, Corticosteroids, Other Drug Types

2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Ocrelizumab, Rituximab, Ofatumumab, Ublituximab

2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide

3) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone, Hydrocortisone

4) By Other Drug Types: Biotin, Ibudilast, Laquinimod, Idebenone

How Are Trends Shaping The Direction Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

Leading companies in the primary progressive multiple sclerosis (PPMS) treatment market are focusing on creating advanced formulations, such as monoclonal antibody drugs, to improve multiple sclerosis therapy. A monoclonal antibody drug aids in multiple sclerosis by specifically targeting immune cells or proteins that initiate inflammation and harm the nervous system, thereby reducing disease activity and slowing the advancement of symptoms. For instance, in February 2024, Roche Pharma India, an India-based pharmaceutical company, introduced Ocrevus (ocrelizumab), a monoclonal antibody drug, for treating multiple sclerosis (MS) in India. Ocrevus is significant as the first and only approved disease-modifying therapy (DMT) for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in the country. The drug operates by targeting CD20-positive B cells, a type of immune cell involved in the abnormal immune response observed in MS. It is administered as a twice-yearly intravenous infusion for only two hours, providing patients with a more convenient and effective treatment alternative.

Which Companies Are Leading Innovation In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

Major companies operating in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Biogen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, BrainStorm Cell Therapeutics Inc., TG Therapeutics Inc., EMD Serono Inc. (Merck KGaA), Mitsubishi Tanabe Pharma Corporation, Sanofi Genzyme, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Viela Bio (Horizon Therapeutics), Receptos (Celgene/Bristol-Myers Squibb), Forward Pharma A/S, InnoCare Pharma, NervGen Pharma Corp., Priovant Therapeutics, Tiziana Life Sciences, Reata Pharmaceuticals, Biohaven Pharmaceutical Holding Company, Anokion SA

Read the full primary progressive multiple sclerosis (ppms) treatment market report here:

https://www.thebusinessresearchcompany.com/report/primary-progressive-multiple-sclerosis-ppms-treatment-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (ppms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24670&type=smp

Browse Through More Reports Similar to the Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market 2026, By The Business Research Company

Multiple Sclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report

Atherosclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

Focal Segmental Glomerulosclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/focal-segmental-glomerulosclerosis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The market for primary progressive multiple sclerosis (ppms) treatments has experienced swift expansion recently. This market is projected to expand from $1.16 billion in 2025 to $1.31 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.7%. Historically, this growth can be ascribed to factors such as restricted treatment options for ppms, the dependence on corticosteroids for managing symptoms, inadequate patient awareness of ppms, an underdeveloped hospital pharmacy infrastructure, and the gradual uptake of immunosuppressants.

The primary progressive multiple sclerosis (ppms) treatment market is projected to expand significantly in the coming years, reaching $2.18 billion by 2030, driven by a compound annual growth rate (CAGR) of 13.5%. This anticipated expansion throughout the forecast period can be ascribed to several factors, including the emergence of targeted monoclonal antibodies, heightened research and development efforts in neurodegenerative conditions, the broadening of hospital and online pharmacy infrastructures, a surge in regulatory approvals for new treatments, and enhanced patient awareness and early detection initiatives. Key trends expected during this period involve an increasing uptake of monoclonal antibodies for ppms, a greater emphasis on managing symptoms and improving quality of life, a growing preference for intravenous drug delivery, the expansion of hospital and specialty pharmacy networks, and the creation of innovative therapeutics and combination treatments.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24670&type=smp

What Key Drivers Are Influencing The Growth Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

The primary progressive multiple sclerosis (PPMS) treatment market is projected to grow in the future due to the increasing need for effective treatments. These treatments are medical interventions that lessen symptoms, improve patient results, or cure a disease or condition. The rising demand for effective treatments is primarily fueled by the increasing occurrence of chronic and complex health conditions, which necessitate sustained management and advanced therapeutic interventions to enhance patient outcomes and quality of life. Specifically for primary progressive multiple sclerosis (PPMS), effective treatments aid in slowing its advancement by targeting inflammation and maintaining neurological function, thereby enhancing long-term quality of life, minimizing disability buildup, and boosting patients’ capacity to manage daily activities with greater independence and stability. As an example, in January 2024, as reported by the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, the count of gene therapies in Phase III clinical trials reached 33 Phase III gene therapy trials in 2023, which was an increase of 10% compared to 2022, marking the first quarterly increase since Q3 2022. Consequently, the escalating demand for effective treatments propels the expansion of the primary progressive multiple sclerosis (PPMS) treatment market.

What Major Segment Divisions Exist Within The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

The primary progressive multiple sclerosis (ppms) treatment market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Immunosuppressants, Corticosteroids, Other Drug Types

2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Ocrelizumab, Rituximab, Ofatumumab, Ublituximab

2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide

3) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone, Hydrocortisone

4) By Other Drug Types: Biotin, Ibudilast, Laquinimod, Idebenone

How Are Trends Shaping The Direction Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

Leading companies in the primary progressive multiple sclerosis (PPMS) treatment market are focusing on creating advanced formulations, such as monoclonal antibody drugs, to improve multiple sclerosis therapy. A monoclonal antibody drug aids in multiple sclerosis by specifically targeting immune cells or proteins that initiate inflammation and harm the nervous system, thereby reducing disease activity and slowing the advancement of symptoms. For instance, in February 2024, Roche Pharma India, an India-based pharmaceutical company, introduced Ocrevus (ocrelizumab), a monoclonal antibody drug, for treating multiple sclerosis (MS) in India. Ocrevus is significant as the first and only approved disease-modifying therapy (DMT) for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in the country. The drug operates by targeting CD20-positive B cells, a type of immune cell involved in the abnormal immune response observed in MS. It is administered as a twice-yearly intravenous infusion for only two hours, providing patients with a more convenient and effective treatment alternative.

Which Companies Are Leading Innovation In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

Major companies operating in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Biogen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, BrainStorm Cell Therapeutics Inc., TG Therapeutics Inc., EMD Serono Inc. (Merck KGaA), Mitsubishi Tanabe Pharma Corporation, Sanofi Genzyme, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Viela Bio (Horizon Therapeutics), Receptos (Celgene/Bristol-Myers Squibb), Forward Pharma A/S, InnoCare Pharma, NervGen Pharma Corp., Priovant Therapeutics, Tiziana Life Sciences, Reata Pharmaceuticals, Biohaven Pharmaceutical Holding Company, Anokion SA

Read the full primary progressive multiple sclerosis (ppms) treatment market report here:

https://www.thebusinessresearchcompany.com/report/primary-progressive-multiple-sclerosis-ppms-treatment-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (ppms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24670&type=smp

Browse Through More Reports Similar to the Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market 2026, By The Business Research Company

Multiple Sclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report

Atherosclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

Focal Segmental Glomerulosclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/focal-segmental-glomerulosclerosis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the primary progressive multiple sclerosis (ppms) treatment market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

The market for primary progressive multiple sclerosis (ppms) treatment has experienced substantial growth in recent times. This market is projected to expand from $1.16 billion in 2025 to $1.31 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 13.7%. Historically, this growth was influenced by factors such as the restricted availability of ppms treatment options, the common use of corticosteroids for managing symptoms, a general lack of patient awareness regarding ppms, an undeveloped infrastructure for hospital pharmacies, and the gradual uptake of immunosuppressants.

The primary progressive multiple sclerosis (ppms) treatment market size is expected to undergo rapid expansion in the coming years. This market is projected to reach $2.18 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.5%. The anticipated growth during this period stems from the introduction of targeted monoclonal antibodies, increased research and development efforts in neurodegenerative disorders, the expansion of hospital and online pharmacy networks, a rise in regulatory approvals for novel therapeutics, and enhanced patient awareness and early diagnosis programs. Significant trends for the forecast period include the increasing adoption of monoclonal antibodies for ppms, a heightened focus on symptom management and quality of life, a growing preference for intravenous drug administration, the expansion of hospital and specialty pharmacy channels, and the development of new therapeutics and combination therapies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24670&type=smp

What Drivers Are Supporting Technological Adoption In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

The primary progressive multiple sclerosis (PPMS) treatment market is anticipated to expand due to the increasing need for successful therapies. These successful therapies encompass medical interventions designed to alleviate symptoms, enhance patient results, or resolve a particular illness or condition. This escalating demand for efficacious treatments primarily stems from the rising occurrence of long-term and intricate health issues, necessitating ongoing care and advanced therapeutic methods to better patient well-being and life quality. Specifically, in primary progressive multiple sclerosis (PPMS), effective treatments contribute to slowing disease progression by addressing inflammation and safeguarding neurological function. This, in turn, leads to an improved long-term quality of life, a decrease in disability progression, and an enhanced capacity for patients to manage their daily routines with increased autonomy and steadiness. An illustrative example, cited in January 2024 by the American Society of Gene & Cell Therapy, a US organization focused on gene and cell therapy, revealed that the number of gene therapies undergoing Phase III clinical trials reached 33 Phase III gene therapy trials in 2023. This marked an increase of 10% compared to 2022, signifying the initial quarterly rise observed since the third quarter of 2022. Consequently, the increasing need for effective treatments is a key factor propelling the expansion of the primary progressive multiple sclerosis (PPMS) treatment market.

Which Segments Are Contributing To The Growth Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

The primary progressive multiple sclerosis (ppms) treatment market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Immunosuppressants, Corticosteroids, Other Drug Types

2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Ocrelizumab, Rituximab, Ofatumumab, Ublituximab

2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide

3) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone, Hydrocortisone

4) By Other Drug Types: Biotin, Ibudilast, Laquinimod, Idebenone

What Trends Are Expected To Impact The Competitive Landscape Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

Companies operating in the primary progressive multiple sclerosis (PPMS) treatment market are concentrating on developing advanced formulations, such as monoclonal antibody drugs, to enhance the treatment of multiple sclerosis. Monoclonal antibody drugs aid in multiple sclerosis by targeting particular immune cells or proteins responsible for inflammation and nervous system damage, which in turn reduces disease activity and delays the advancement of symptoms. For instance, Roche Pharma India, an India-based pharmaceutical company, launched Ocrevus (ocrelizumab) in February 2024 as a monoclonal antibody drug specifically for treating multiple sclerosis (MS) in India. Ocrevus stands out as the first and sole approved disease-modifying therapy (DMT) in the country for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). The drug functions by targeting CD20-positive B cells, a type of immune cell implicated in the abnormal immune response observed in MS. It is administered via a twice-yearly intravenous infusion lasting only two hours, offering patients a more convenient and efficient treatment choice.

Who Are The Core Companies Influencing Trends In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

Major companies operating in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Biogen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, BrainStorm Cell Therapeutics Inc., TG Therapeutics Inc., EMD Serono Inc. (Merck KGaA), Mitsubishi Tanabe Pharma Corporation, Sanofi Genzyme, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Viela Bio (Horizon Therapeutics), Receptos (Celgene/Bristol-Myers Squibb), Forward Pharma A/S, InnoCare Pharma, NervGen Pharma Corp., Priovant Therapeutics, Tiziana Life Sciences, Reata Pharmaceuticals, Biohaven Pharmaceutical Holding Company, Anokion SA

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/primary-progressive-multiple-sclerosis-ppms-treatment-global-market-report

Which Regions Are Projected To Dominate The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market In The Coming Years?

North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (ppms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24670&type=smp

Browse Through More Reports Similar to the Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market 2026, By The Business Research Company

Multiple Sclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report

Atherosclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

Focal Segmental Glomerulosclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/focal-segmental-glomerulosclerosis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

The primary progressive multiple sclerosis (PPMS) treatment market size is expected to reach $1.92B by 2029 at a 13.5% CAGR, driven by innovative therapies, advanced diagnostics, and personalized medicine.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Heading Into 2029?

In recent times, there has been a quick surge in the size of the primary progressive multiple sclerosis (ppms) treatment market. It is forecasted to expand from $1.02 billion in 2024 to $1.16 billion in 2025, with a compound annual growth rate (CAGR) of 13.7%. Factors such as a higher prevalence of PPMS in the older population, escalated awareness and comprehension of PPMS among patients and healthcare practitioners, increased investment in R&D for PPMS therapies, a growing preference for disease-modifying therapies (DMTs), and wider government initiatives and financial support for innovative PPMS treatments contribute to the growth experienced during this historical period.

In the upcoming years, it is predicted that the primary progressive multiple sclerosis (ppms) treatment market will witness substantial growth, reaching a value of $1.92 billion in 2029, at a 13.5% compound annual growth rate (CAGR). This growth can be tied to various elements such as the rising number of clinical trials for new PPMS drugs, advancements in diagnosis methods, the escalating demand for personalized and targeted medical treatments, increased healthcare infrastructure and an uptick in collaborations and partnerships between pharmaceutical companies. Key trends impacting this predicted growth include advancements in therapies that slow PPMS progression, the integration of research on biomarkers for tailored treatment strategies, technology-enabled advancements in MRI and other diagnostic imaging techniques, headway in the study of neuroprotective and remyelination drugs, and advancements in using genetic and molecular profiling for patient categorization.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24670&type=smp

Which Factors Are Pushing The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Forward?

Anticipated growth in the primary progressive multiple sclerosis (PPMS) treatment market can be attributed to an increasing demand for effective therapeutic interventions. Such treatments are instrumental in minimizing symptoms, enhancing patient prognosis, or in some cases even curing the disorder or disease completely. This increasing demand is usually triggered by a surge in chronic and intricate health conditions which necessitate long-term management along with advanced therapeutic measures for improving the patients’ quality of life and overall condition. These effective treatments act by tackling inflammation and maintaining neurological functions, thereby delaying the progression of primary progressive multiple sclerosis (PPMS). This not only improves the quality of life over time, but it also slows down disability accumulation while bolstering the patients’ capacity to handle everyday tasks more independently and stably. As an example, in January 2024, the American Society of Gene & Cell Therapy, a US-based gene and cell therapy organization, reported that the number of gene therapies in Phase III clinical trials rose to 33 from 30 in 2023 – a 10% increase compared to 2022, and was the first quarter-on-quarter rise since Q3 2022. As such, it’s clear that the mounting demand for effective treatments is fueling the growth of the primary progressive multiple sclerosis (PPMS) treatment market.

Which Segment Held The Largest Share In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market In 2025?

The primary progressive multiple sclerosis (PPMS) treatment market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Immunosuppressants, Corticosteroids, Other Drug Types

2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Ocrelizumab, Rituximab, Ofatumumab, Ublituximab

2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide

3) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone, Hydrocortisone

4) By Other Drug Types: Biotin, Ibudilast, Laquinimod, Idebenone

How Are Key Trends Driving Expansion In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Industry?

Major corporations active in the market for primary progressive multiple sclerosis (PPMS) treatment are prioritizing the invention of novel formulations, such as monoclonal antibody drugs, to improve multiple sclerosis treatment. Monoclonal antibody medications target specific inflammatory-causing immune cells or proteins and diminish damage to the nervous system, thereby minimizing disease activity and slowing symptom progression. For example, in February 2024, Ocrevus (ocrelizumab), a monoclonal antibody medication for MS, was launched in India by Roche Pharma India, a pharmaceutical company based in the country. Ocrevus holds the distinction of being the only approved disease-modifying therapy (DMT) for both relapsing-remitting multiple sclerosis (RRMS) and PPMS in India. The drug operates by targeting CD20-positive B cells, which are immune cells involved in the irregular immune reaction observed in MS. Administered through a bi-annual intravenous infusion lasting only two hours, it offers a more flexible and effective solution for patients.

Which Organizations Are Driving Progress In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Industry?

Major companies operating in the primary progressive multiple sclerosis (PPMS) treatment market are F. Hoffmann-La Roche Ltd., Bayer HealthCare Pharmaceuticals Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, Brainstorm Cell Therapeutics Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/primary-progressive-multiple-sclerosis-ppms-treatment-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Industry?

North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (PPMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24670&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model